San Diego-based Maravai LifeSciences, which contains companies that provide tools and services to pharmaceutical and biopharmaceutical research and development companies, has announced the hiring of four senior management executives. The company stated the new hires have assumed key positions in two of Maravai LifeSciences operating businesses: TriLink BioTechnologies and Cygnus Technologies.
Joining the TriLink BioTechnologies team are Brian Neel, chief operating officer; Michael Houston, chief scientific officer; and Mike DeMayo, vice president of commercial operations, according to a May 1 news release.
Neel brings more than 15 years of experience in the life science and diagnostic industries at Synthetic Genomics, GenMark Diagnostics and Thermo Fisher Scientific (formerly known as Life Technologies). He specializes in developing and optimizing manufacturing sites and in operations management.
Houston, who holds a doctorate in bioorganic chemistry, has worked for a range of biotechnology and pharmaceutical companies, including PhaseRx, Marina Biotech, Ascent Therapeutics and Nastech Pharmaceutical. He specializes in oligonucleotide synthesis and therapeutic development.
DeMayo brings more than 30 years of sales and marketing experience to Maravai LifeSciences and has worked for a range of leading companies, including Affymetrix, PerkinElmer Life Sciences, Applied Biosystems and Agilent Technologies.
Christine Dolan joins the Cygnus Technologies management team as its chief operating officer.
Dolan comes to Cygnus from Catalent, where she was senior vice president of product development. During her eight-year tenure at Catalent she served in a series of senior executive positions, including vice president of global operations. Previously she held senior management roles at GE Healthcare and Amersham Health.
Maravai LifeSciences is a portfolio company of GTCR, a private equity firm based in Chicago, that focuses on investing in growth companies in financial services, technology and information services, and healthcare. The company said its portfolio includes Vector Laboratories, TriLink BioTechnologies, Cygnus Technologies and Glen Research.